SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Caribou Biosciences, Inc.

NEW YORK, 24 June 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. (“Caribou” or the “Company”) (NASDAQ: CRBU). Such investors are advised to contact Danielle Peyton at (email protected) or 646-581-9980, extension 7980.

The investigation concerns whether Caribou and certain of its officers and/or directors engaged in securities transactions. Fraud or other unlawful business practices.

(Click here for information on joining the class action lawsuit.)

At June 2, 2024Caribou issued a press release announcing that the company “has presented updated clinical data from the ongoing Phase 1 ANTLER trial indicating that a single dose of CB-010, a readily available, off-the-shelf anti-CD19 CAR-T cell therapy with PD-1 knockout, has the potential to rival approved autologous CAR-T cell therapies in terms of safety, efficacy and durability.” Following Caribou’s announcement, analysts at Evercore downgraded the stock to “in line” and lowered the price target to 3,00 € out of 13,00 €and stated that they were “not yet convinced” that Caribou’s therapy “will be competitive and that they would have to wait until data were available in the first half of 2025.”

Following this news, Caribou’s share price fell 0.734 USD per share or 15.52% and closed at 2,145 USD per share on June 3, 2024.

Pomerantz LLP, with offices in new York, Chicago, Los Angeles, London, ParisAnd Tel-Avivis considered one of the leading law firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. PomerantzKnown as the dean of class action lawyers, Pomerantz was a pioneer in the field of securities class action litigation. Today, more than 85 years later, Pomerantz continues the tradition he established and fights for the rights of victims of securities class action litigation. FraudBreach of fiduciary duty and corporate misconduct. The firm has won billions of dollars in damages on behalf of class action plaintiffs. See www.pomlaw.com.

Attorney advertising. Past results do not guarantee similar results.

CONTACT:
Danielle Peyton
Pomerantz LLP
(email protected)
646-581-9980 extension 7980

Never miss a story from Pomerantz LLP again.